AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36894940 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroimaging data (MRI and EEG)
Number of subjects: 800
Study 36894940 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain Positron Emission Tomography (PET)
Number of subjects: 800
Study 36894966 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 662
Study 36894966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 662
Study 36894985 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampled HPV testing, visualization of the cervix with acetic acid (VIA), cryotherapy, mobile colposcopy, thermal ablation, loop electrosurgical excision procedure (LEEP)
Number of subjects: 0
Study 36894985 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel diagnostic tests (QG-MPH®, Prevo-Check®, PT Monitor®)
Number of subjects: 0
Study 36894992 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 12
Study 36895006 — intervention group
Group type: EXPERIMENTAL
Intervention: BEAM program (10 weeks)
Number of subjects: 0
Study 36895006 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (MoodMission)
Number of subjects: 0
Study 36895006 — intervention group
Group type: EXPERIMENTAL
Intervention: BEAM program
Number of subjects: 0
Study 36895062 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-anthracycline HER2-targeted treatment regimen with echocardiograms every 6 months
Number of subjects: 190
Study 36895157 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel endovascular venous anastomotic device
Number of subjects: 158
Study 36895163 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal therapy (FT) using cryotherapy
Number of subjects: 28
Study 36895330 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithm eXtreme Gradient Boosting (XGBoost)
Number of subjects: 16736
Study 36895331 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide (LEF) combined with prednisone
Number of subjects: 116
Study 36895331 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with prednisone
Number of subjects: 116
Study 36895483 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific 3-D surgical navigation system
Number of subjects: 30
Study 36895483 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard procedure)
Number of subjects: 30
Study 36895618 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Qigong classes
Number of subjects: 14
Study 36895801 — intervention group
Group type: EXPERIMENTAL
Intervention: CRE infections (cUTI, pneumonia, cIAI, BSI-OS)
Number of subjects: 235
Study 36895801 — intervention group
Group type: COMPARATOR
Intervention: CSE controls
Number of subjects: 235
Study 36896366 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming intervention (n=21)
Number of subjects: 52
Study 36896366 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise protocol (control group, n=25)
Number of subjects: 52
Study 36896702 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 vaccine
Number of subjects: 662
Study 36896716 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital observation on oral diuretics (OOD)
Number of subjects: 468
Study 36896716 — intervention group
Group type: COMPARATOR
Intervention: Control (no in-hospital OOD)
Number of subjects: 468
Study 36896967 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent screening and treatment of malaria (ISTp)
Number of subjects: 1786
Study 36896967 — intervention group
Group type: COMPARATOR
Intervention: Routine ANC (control)
Number of subjects: 1786
Study 36897008 — intervention group
Group type: EXPERIMENTAL
Intervention: DPMAS with sequential low-volume plasma exchange (LPE)
Number of subjects: 50
Study 36897008 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive medical treatment (Control)
Number of subjects: 50
Study 36897127 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP-based noninvasive prenatal screening results suspicious for maternal malignancy
Number of subjects: 2004428
Study 36897140 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled intravenous ketorolac (30 mg every 6 hours)
Number of subjects: 148
Study 36897140 — intervention group
Group type: COMPARATOR
Intervention: Placebo (30 mg every 6 hours)
Number of subjects: 148
Study 36897140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 36897140 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled intravenous ketorolac
Number of subjects: 148
Study 36897140 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled intravenous ketorolac and Placebo
Number of subjects: 148
Study 36897162 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant cancer and SUI surgery
Number of subjects: 532
Study 36897162 — intervention group
Group type: COMPARATOR
Intervention: Cancer surgery alone
Number of subjects: 532
Study 36897180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1830
Study 36897180 — intervention group
Group type: EXPERIMENTAL
Intervention: Fezolinetant 30 mg
Number of subjects: 1830
Study 36897180 — intervention group
Group type: EXPERIMENTAL
Intervention: Fezolinetant 45 mg
Number of subjects: 1830
Study 36897182 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance of cervical, scapular, trunk, and upper extremity muscles
Number of subjects: 36
Study 36897182 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance of cervical flexor, anterior trunk flexor, and upper extremity muscles
Number of subjects: 36
Study 36897182 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance of upper extremity, scapular region, and trunk muscles
Number of subjects: 36
Study 36897202 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Specific Functional Scale (PSFS)
Number of subjects: 32
Study 36897226 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based contraception education intervention
Number of subjects: 25
Study 36897239 — intervention group
Group type: EXPERIMENTAL
Intervention: vPatch (active group)
Number of subjects: 59
Study 36897239 — intervention group
Group type: COMPARATOR
Intervention: Sham device (control group)
Number of subjects: 59
Study 36897251 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19 CAR T-cell therapy combined with autologous CD19+ feeding T cells (FTCs) and tyrosine kinase inhibitor (TKI) as consolidation therapy.
Number of subjects: 13
Study 36897251 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19 CAR T-cell therapy combined with autologous CD19+ feeding T cells (FTCs) and TKI as consolidation therapy.
Number of subjects: 13
Study 36897310 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriosis treatment
Number of subjects: 0
Study 36897310 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine treatment
Number of subjects: 0
Study 36897413 — intervention group
Group type: EXPERIMENTAL
Intervention: faricimab 6.0 mg every 8 weeks (Q8W)
Number of subjects: 60
Study 36897413 — intervention group
Group type: EXPERIMENTAL
Intervention: faricimab 6.0 mg per personalized treatment interval (PTI)
Number of subjects: 60
Study 36897413 — intervention group
Group type: COMPARATOR
Intervention: aflibercept 2.0 mg every 8 weeks (Q8W)
Number of subjects: 60
Study 36897427 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0
Study 36897427 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 0
Study 36897458 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoviral vectors
Number of subjects: 204
Study 36897464 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted rehabilitation (RR) for 60 min, 5 days a week, for 6 weeks
Number of subjects: 41
Study 36897464 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation (CR) with individualized upper-limb rehabilitation
Number of subjects: 41
Study 36897535 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptive rehabilitation
Number of subjects: 55
Study 36897535 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization
Number of subjects: 55
Study 36897535 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 55
Study 36897544 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan 50 mg
Number of subjects: 16
Study 36897544 — intervention group
Group type: COMPARATOR
Intervention: Vonoprazan 20 mg
Number of subjects: 16
Study 36897544 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg
Number of subjects: 16
Study 36897592 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% discount on eligible fruits and vegetables
Number of subjects: 2744
Study 36897592 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefilled shopping carts with tailored fruit and vegetable items (default options)
Number of subjects: 2744
Study 36897592 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of discount and default options
Number of subjects: 2744
Study 36897592 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 2744
Study 36897592 — intervention group
Group type: EXPERIMENTAL
Intervention: Discount condition
Number of subjects: 2744
Study 36897592 — intervention group
Group type: EXPERIMENTAL
Intervention: Default condition
Number of subjects: 2744
Study 36897592 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination condition
Number of subjects: 2744
Study 36897592 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 2744
Study 36897642 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity tracker
Number of subjects: 30
Study 36897642 — intervention group
Group type: COMPARATOR
Intervention: SWOT analysis
Number of subjects: 30
Study 36897745 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR) left atrioventricular coupling index (LACI)
Number of subjects: 0
Study 36897745 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest and ergometer-stress CMR
Number of subjects: 0
Study 36897799 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-processed diet
Number of subjects: 20
Study 36897799 — intervention group
Group type: COMPARATOR
Intervention: Unprocessed diet
Number of subjects: 20
Study 36897803 — intervention group
Group type: EXPERIMENTAL
Intervention: Iterative Metal Artifact Reduction (IMAR)
Number of subjects: 50
Study 36897803 — intervention group
Group type: COMPARATOR
Intervention: Standard kernel
Number of subjects: 50
Study 36897803 — intervention group
Group type: COMPARATOR
Intervention: Sharp kernel
Number of subjects: 50
Study 36897803 — intervention group
Group type: COMPARATOR
Intervention: Virtual Monoenergetic Imaging (VMI) levels >70 keV
Number of subjects: 50
Study 36897834 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 1669
Study 36897834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1669
Study 36897863 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy (RAT)
Number of subjects: 0
Study 36897863 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR)-based neuromotor rehabilitation
Number of subjects: 0
Study 36897863 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic and VR devices
Number of subjects: 0
Study 36897877 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide mass drug administration (cMDA) for soil-transmitted helminths (STH)
Number of subjects: 3
Study 36897877 — intervention group
Group type: EXPERIMENTAL
Intervention: Existing infrastructure from other NTD programs like lymphatic filariasis (LF)
Number of subjects: 3
Study 36897877 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement of local leaders and community groups
Number of subjects: 3
Study 36897877 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of cMDA with immunization, maternal child health, and non-communicable disease control programs
Number of subjects: 3
Study 36898078 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib and Avelumab
Number of subjects: 40
Study 36898233 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg/day for 1 year
Number of subjects: 2840
Study 36898233 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 year
Number of subjects: 2840
Study 36898269 — intervention group
Group type: EXPERIMENTAL
Intervention: Xerosis cutis
Number of subjects: 314
Study 36898269 — intervention group
Group type: EXPERIMENTAL
Intervention: Intertrigo
Number of subjects: 314
Study 36898269 — intervention group
Group type: EXPERIMENTAL
Intervention: Incontinence-associated dermatitis
Number of subjects: 314
Study 36898269 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin tears
Number of subjects: 314
Study 36898269 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure ulcers
Number of subjects: 314
Study 36898292 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-paclitaxel
Number of subjects: 0
Study 36898292 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan-paclitaxel
Number of subjects: 0
Study 36898292 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-paclitaxel-bevacizumab
Number of subjects: 0
Study 36898292 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan-paclitaxel-bevacizumab
Number of subjects: 0
Study 36898363 — intervention group
Group type: EXPERIMENTAL
Intervention: SMARTCare intervention (online SM education program I-Can Manage + 5 sessions of telephone cancer coaching)
Number of subjects: 62
Study 36898363 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 62
Study 36898361 — intervention group
Group type: COMPARATOR
Intervention: Usual care arm of the GAP70+ trial
Number of subjects: 369
Study 36898393 — intervention group
Group type: EXPERIMENTAL
Intervention: Nexvax2 (non-homozygous group)
Number of subjects: 179
Study 36898393 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-homozygous group)
Number of subjects: 179
Study 36898393 — intervention group
Group type: EXPERIMENTAL
Intervention: Nexvax2 (homozygous group)
Number of subjects: 179
Study 36898393 — intervention group
Group type: COMPARATOR
Intervention: Placebo (homozygous group)
Number of subjects: 179
Study 36898393 — intervention group
Group type: EXPERIMENTAL
Intervention: Nexvax2
Number of subjects: 179
Study 36898393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 36898391 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated patients (booster and two doses)
Number of subjects: 1909
Study 36898391 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated patients
Number of subjects: 1909
Study 36898391 — intervention group
Group type: COMPARATOR
Intervention: Pre-vaccination phase
Number of subjects: 1909
Study 36898391 — intervention group
Group type: COMPARATOR
Intervention: Alpha-delta phase
Number of subjects: 1909
Study 36898391 — intervention group
Group type: COMPARATOR
Intervention: Omicron phase
Number of subjects: 1909
Study 36898400 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolised Ad5-nCoV
Number of subjects: 356
Study 36898400 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular Ad5-nCoV
Number of subjects: 356
Study 36898400 — intervention group
Group type: COMPARATOR
Intervention: CoronaVac
Number of subjects: 356
Study 36898606 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Bereavement Program (FBP)
Number of subjects: 244
Study 36898606 — intervention group
Group type: COMPARATOR
Intervention: Literature comparison condition
Number of subjects: 244
Study 36898607 — intervention group
Group type: EXPERIMENTAL
Intervention: MFG facilitated by parent peers (MFG-PP)
Number of subjects: 636
Study 36898607 — intervention group
Group type: EXPERIMENTAL
Intervention: MFG facilitated by community health workers (MFG-CHW)
Number of subjects: 636
Study 36898607 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 636
Study 36898607 — intervention group
Group type: EXPERIMENTAL
Intervention: MFG-PP and MFG-CHW
Number of subjects: 636
Study 36898748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 2500
Study 36898748 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam
Number of subjects: 2500
Study 36898751 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day course of hydrocortisone and fludrocortisone
Number of subjects: 1800
Study 36898751 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day standard course of dexamethasone
Number of subjects: 1800
Study 36898751 — intervention group
Group type: COMPARATOR
Intervention: Fludrocortisone
Number of subjects: 1800
Study 36898751 — intervention group
Group type: COMPARATOR
Intervention: Placebo for hydrocortisone and fludrocortisone
Number of subjects: 1800
Study 36898751 — intervention group
Group type: COMPARATOR
Intervention: Placebo for dexamethasone
Number of subjects: 1800
Study 36898758 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral autoregulation using PRx (Pressure Reactivity Index)
Number of subjects: 135
Study 36898758 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral perfusion pressure measurements
Number of subjects: 135
Study 36898758 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluctuations in measured parameters
Number of subjects: 135
Study 36898767 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional elastic band exercise
Number of subjects: 200
Study 36898767 — intervention group
Group type: COMPARATOR
Intervention: Usual exercise-based care
Number of subjects: 200
Study 36898933 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 0
Study 36898933 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor T-cell therapy
Number of subjects: 0
Study 36898933 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncolytic virotherapy
Number of subjects: 0
Study 36898939 — intervention group
Group type: EXPERIMENTAL
Intervention: QFR-based virtual PCI
Number of subjects: 300
Study 36898939 — intervention group
Group type: COMPARATOR
Intervention: Angiography-based PCI (standard of care)
Number of subjects: 300
Study 36898948 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy
Number of subjects: 0
Study 36898948 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 0
Study 36898948 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal therapy/ablation treatment
Number of subjects: 0
Study 36898948 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and immunotherapy
Number of subjects: 0
Study 36898948 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathologic changes
Number of subjects: 0
Study 36898948 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel therapies
Number of subjects: 0
Study 36898949 — intervention group
Group type: EXPERIMENTAL
Intervention: Using Peer Support to Aid in Prevention and Treatment in Prediabetes
Number of subjects: 355
Study 36898949 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 355
Study 36899125 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACYW-TT booster vaccination
Number of subjects: 0
Study 36899125 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACYW-TT booster vaccination with co-administration of MenB vaccine
Number of subjects: 0
Study 36899125 — intervention group
Group type: COMPARATOR
Intervention: MCV4-CRM-primed participants receiving MenACYW-TT alone
Number of subjects: 0
Study 36899292 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront open surgical necrosectomy
Number of subjects: 247
Study 36899292 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic drainage of pancreatic necrosis
Number of subjects: 247
Study 36899292 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 247
Study 36899292 — intervention group
Group type: EXPERIMENTAL
Intervention: History of uncontrolled arterial hypertension
Number of subjects: 247
Study 36899292 — intervention group
Group type: EXPERIMENTAL
Intervention: qSOFA
Number of subjects: 247
Study 36899292 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal failure
Number of subjects: 247
Study 36899292 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodynamic failure
Number of subjects: 247
Study 36899292 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholangitis
Number of subjects: 247
Study 36899292 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal compartment syndrome
Number of subjects: 247
Study 36899292 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal/intra-abdominal bleeding
Number of subjects: 247
Study 36899310 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive myocardial work (MW) parameters during isovolumic relaxation (IVR)
Number of subjects: 448
Study 36899310 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 448
Study 36899317 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary bouts of 1-to-10 minutes (mean 95.1, SD 25.0)
Number of subjects: 460
Study 36899317 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary bouts of >10-to-30 minutes (mean 13.3, SD 3.4)
Number of subjects: 460
Study 36899317 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary bouts of >30 minutes (mean 3.5, SD 1.9)
Number of subjects: 460
Study 36899351 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured educational intervention involving lower limb physical exercise and daily ambulation guidelines
Number of subjects: 224
Study 36899351 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment in primary care (cleansing, debridement, healing in a moist environment, multilayer compression therapy)
Number of subjects: 224
Study 36899369 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan 20 mg once daily
Number of subjects: 80
Study 36899369 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg once daily
Number of subjects: 80
Study 36899430 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin 700mg + 8mg vitamin E + 50mg phosphatidylcholine daily
Number of subjects: 0
Study 36899430 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin 700mg + 8mg vitamin E + 50mg phosphatidylcholine daily (Control)
Number of subjects: 0
Study 36900181 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine treatment
Number of subjects: 272
Study 36900279 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental Abutting Esophagus-Sparing (SAES) radiotherapy (45 Gy in 3 Gy daily fractions over 3 weeks)
Number of subjects: 30
Study 36900279 — intervention group
Group type: COMPARATOR
Intervention: Non-Segmental Abutting Esophagus-Sparing (non-SAES) radiotherapy
Number of subjects: 30